|Dr. Wei-Wu He||Co-Founder & Chairman||N/A||N/A||1965|
|Mr. Sizhen Wang||Co-Founder, CEO & Director||N/A||N/A||1977|
|Dr. Hai Yan||Co-Founder, Chief Scientific Officer & Director||N/A||N/A||1968|
|Mr. Ce Xu||Chief Financial Officer||N/A||N/A||1982|
|Mr. Ying Hong||Chief Operating Officer||N/A||N/A||1972|
|Dr. Yuchen Jiao M.D., Ph.D.||Chief Technology Officer||N/A||N/A||1978|
|Dr. Yun-Fu Hu Ph.D.||Chief Medical Officer||N/A||N/A||1963|
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Genetron Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.